A Basic FGF Mimetic Biobetter for Mitigation of Acute Gastrointestinal Radiation Syndrome

Speaker
  • Research Associate Professor, University of Florida
    Biography
      Steven Swarts currently works at the Department of Radiation Oncology, University of Florida. Steven does research in cancer research, development of mitigators of acute radiation syndromes, assay development of biomarkers of radiation effects, and environmental chemistry. Their most recent publication is 'Thoracic gamma irradiation-induced obesity in C57BL/6 female mice'.

    Abstract

    In the event of a radiological or nuclear disaster, there will be a need for therapies that can mitigate the acute hematopoietic and gastrointestinal (GI) radiation syndromes expected to develop in many of the victims of the disaster. Currently, there are FDA approved G-CSF and GM-CSF agents for mitigating the myelosuppression associated with the hematopoietic syndrome. However, an effective mitigation agent for acute GI syndrome is currently missing from our clinical armamentarium. Basic FGF (FGF2) benefits both GI and hematopoietic
    syndromes in mouse models. However, natural FGF2 is severely depleted by total-body irradiation in humans, and replacement with hrFGF2 has logistical challenges and production costs that make clinical use and strategic stockpiling unrealistic. We hypothesize that FGF-P, a small FGF2 mimetic peptide, mitigates acute radiation-induced GI syndrome through a variety of cooperating mechanisms, including decreased mucosal cell loss, improved proliferation of small bowel mucosa and gut barrier function, and reduced bacterial translocation. It also helps maintain progenitor cells through signaling pathways that mimic natural FGFs. Our current preclinical studies of FGF-P in rodent survival and mechanistic studies are demonstrating these expected benefits, including improved GI barrier function, electrolyte transport, and mitogenesis for at least 30-day post-irradiation. This is resulting in increased survival time and the number of survivors when FGF-P is given subcutaneously beginning 24 hours post radiation exposure. In an effort to more fully understand the mechanisms by which FGF-P is mitigating GI-ARS we are examining a number of pro- and anti-inflammatory cytokine and chemokine beginning prior to irradiation, within the first 10 days following administration of FGF-P to 30 post-irradiation. The cytokine and chemokine studies are being conducted with the use of the Bio-Rad Bio-Plex Pro 23-plex Mouse and Rat cytokine kits, and 33-plex mouse chemokine kit, run on a Luminex 200 instrument. These multi-plex assay systems provide us with the needed breadth of cytokine and chemokine coverage for our mechanistic studies while minimizing the volume of plasma sample needed to perform the assay. From the results of the cytokine and chemokine studies in the rodent models, we will be able to identify common markers of efficacy of the FGF-P in the rodent models that could be used to translate the results of these pre-clinical studies to higher animal models and ultimately into humans as we advance our drug development efforts with the goal of gaining FDA approval of the use of FGF-P as a mitigator of GI-ARS using the Animal Rule.


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    APR 01, 2021 8:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    FEB 24, 2021 10:00 AM PST
    C.E. CREDITS
    FEB 24, 2021 10:00 AM PST
    DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
    DEC 15, 2020 10:00 AM PST
    C.E. CREDITS
    DEC 15, 2020 10:00 AM PST
    DATE: December 15, 2020 TIME: 10:00am PST Scientists from Thermo Fisher Scientific will walk us through the world of microorganisms. They will discuss their most recent research on viruses,...
    SEP 03, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 03, 2020 9:00 AM PDT
    DATE: September 3, 2020 TIME: 09:00am PT, 12:00pm ET xxx Learning Objectives: xxx Webinars will be available for unlimited on-demand viewing after live event. LabRoots is approved as a provi...
    DEC 03, 2020 4:30 PM PST
    C.E. CREDITS
    DEC 03, 2020 4:30 PM PST
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...

    A Basic FGF Mimetic Biobetter for Mitigation of Acute Gastrointestinal Radiation Syndrome


    No demographic data is available yet for this event.


    Show Resources
    Loading Comments...
    Show Resources